Back to News
Market Impact: 0.2
āshibio Presents Preliminary Efficacy Data for Andecaliximab Demonstrating an 86.2% Reduction in New Flare-Up Rate in Patients with FOP
Source: Business Wire
Healthcare & Biotech
āshibio announced that preliminary efficacy data from Part 1 of its Phase 2/3 study of andecaliximab for FOP will be presented. The article provides no efficacy results, numerical data, or presentation date.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- Alaunos completes Velaris acquisition, raises $350 million